Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1754-1755

  Patron, Roberto L ^a   Climo, Michael W ^a,b,d   Goldstein, Beth P ^c   Archer, Gordon L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Neurology Service   (United States)

^c AMBI Inc   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSTAPHIN; RECOMBINANT LYSOSTAPHIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AORTA VALVE DISEASE; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS;

EID: 0032779487     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1754     Document Type: Article

References (16)

1. Climo, M. W., S. M. Markowitz, D. S. Williams, C. G. Hale-Cooper, and G. L. Archer. 1997. Comparison of in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species. J. Antinmicrob. Chemother. 40:59-66.
2. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
3. Dixon, R. E., J. S. Goodman, and M. G. Koenig. 1968. Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J. Biol Med. 41:62-68.
4. Goldberg, L. M., J. M. DeFranco, C. Watanakunakorn, and M. Hamburger. 1967. Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin, p. 45-53. Antimicrob. Agents Chemother. 1966.
5. Harrison, E. F., and C. B. Cropp. 1967. Therapeutic activity of lysostaphin in experimental staphylococcal infections. Can. J. Microbiol. 13:93-97.
6. Harrison, E. F., and W. A. Zygmunt. 1967. Lysostaphin in experimental renal infections. J. Bacteriol. 93:520-524.
7. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguru, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-146.
8. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A4, 4th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Perlman, B. B., and L. R. Freedman. 1971. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-213.
10. Ploy, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
11. Schaffner, W., M. A. Melly, J. H. Hash, and M. G. Koenig. 1967. Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J. Biol. Med. 39:215-229.
12. Schaffner, W., M. A. Melly, and M. G. Koenig. 1967. Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. Yale J. Biol. Med. 39:230-244.
13. Schuhardt, V. T., and C. A. Schindler. 1964. Lysostaphin therapy in mice infected with Staphylococcus aureus. J. Bacteriol. 88:815-816.
14. Stark, F. R., C. Thornsvard, E. P. Flannery, and M. S. Artenstein. 1974. Systemic lysostaphin in man. Apparent antimicrobial activity in a neutropenic patient. N. Engl. J. Med. 291:239-240.
15. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
16. Zygmunt, W., and P. A. Tavormina. 1972. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug. Res. 16:309-333.